Seeking Alpha


  • The Strengthened Case For 'Risk Off': Liking Extra Cash And Some Other 'Value' Assets
    DoctoRx AAPL, AMZN, BMY Mon, Nov. 16, 1:20 PM
  • Is Gilead Still An Attractive Long Term Proposition?
    Bryson Kacha ABBV, AMGN, BIIB Mon, Nov. 16, 11:55 AM
  • Biotech Weekly: Stories To Track Into SABCS, Oncothyreon And Puma Biotechnology
    Daniel Ward PBYI, ONTY Mon, Nov. 16, 11:29 AM
  • Anavex: Interview With Professor Tangui Maurice
    Kanak Kanti De AVXL Mon, Nov. 16, 10:23 AM
  • Anavex: Response To 3 Recent Bearish Articles
    Kanak Kanti De AVXL Mon, Nov. 16, 10:21 AM
  • Bluebird Bio: Waiting For Sickle Cell Disease Data
    Kanak Kanti De BLUE Mon, Nov. 16, 8:31 AM
  • Premarket Biotech Digest: Harvoni's Label Expansion, AstraZeneca's Tagrisso Approved, KaloBios Winds Down
    Kanak Kanti De ABBV, ACAD, ADHD Mon, Nov. 16, 8:23 AM
  • BioMarin Looks Attractive As Biotech Turns Around
    Mayer Winkler ABBV, IBB, BMRN Mon, Nov. 16, 7:39 AM
  • Will The New Indications For Harvoni Increase Gilead Sciences' U.S. Sales?
    Arie Goren GILD Mon, Nov. 16, 7:29 AM
  • Do You Buy Stocks Or Stock Symbols?
    Darren Homrighausen GILD Mon, Nov. 16, 6:34 AM
  • 8 Reasons Why Gilead Is A Better Investment Than Intel And 3 Reasons Why It Is Not
    Anchorite INTC, GILD Mon, Nov. 16, 6:29 AM
  • Arena- Belviq Scripts See Small Rise But Still Lag Sector Where It Counts
    Spencer Osborne OREX, VVUS, ARNA Mon, Nov. 16, 6:07 AM
  • Concordia Healthcare: Opportunity
    Inzkeeper CXRX Sat, Nov. 14, 12:56 PM
  • ZS-9 Label May Restrict Use In Patients With Renal Disease, Heart Failure, And Hypertension
    White Coat Mafia ZSPH, RLYP Fri, Nov. 13, 1:50 PM
  • Update: Aerosurf P2A Readout Shows Mixed Results, But Investment Case Remains
    Modis DSCO Fri, Nov. 13, 12:46 PM
  • MannKind Share Sale Strategy
    Maredin Capital Advisors MNKD Fri, Nov. 13, 11:34 AM
  • Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward
    Stephen Simpson, CFA SNY, ISIS, ALNY Fri, Nov. 13, 9:12 AM
  • Gilead: Like Watching Paint Dry In 2015
    Bret Jensen GILD Fri, Nov. 13, 9:06 AM
  • Upcoming Events - Readouts Approach For Cerulean And BioCryst
    EP Vantage CERU, BCRX Thu, Nov. 12, 12:53 PM
  • Arena Conference Call Offers Honesty To Investors
    Spencer Osborne OREX, VVUS, ARNA Thu, Nov. 12, 11:26 AM
  • Gilead: The Margin Of Safety Will Benefit Long-Term Investors
    Jeremy McKinzie GILD Thu, Nov. 12, 8:44 AM
  • Premarket Biotech Digest: Anavex Patient Comments, Focus On Science, Horizon Tumbles
    Kanak Kanti De AIMT, ALNY, ARDM Thu, Nov. 12, 8:35 AM
  • Cambrex - Increasing Estimates For FY:15 And FY:16
    Singular Research CBM Thu, Nov. 12, 2:04 AM
  • MannKind's Efforts To Survive
    David Butler SNY, MNKD Wed, Nov. 11, 6:41 PM
  • Neurocrine Biosciences Has The Flash And The Cash
    Stephen Simpson, CFA ABBV, NBIX Wed, Nov. 11, 4:00 PM
  • Anavex Life Sciences: A Promotional Company With Too Many Red Flags
    Jean Fonteneau IBB, AVXL Wed, Nov. 11, 10:02 AM
  • Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars
    Kanak Kanti De AAVL, ADMA, AEGR Wed, Nov. 11, 8:17 AM
  • IPO Preview: Wave Life Sciences Pte Ltd.
    IPOdesktop WVE Wed, Nov. 11, 8:09 AM
  • IPO Preview: Voyager Therapeutics
    IPOdesktop VYGR Wed, Nov. 11, 7:53 AM
  • Zafgen Beats The Street, Preserves Cash - Is It Still An Attractive Play?
    Spencer Osborne ZFGN Wed, Nov. 11, 6:41 AM
  • Amgen's 27% Dividend Increase For 2016 Is A Sign Of Its Strength
    David White AMGN Tue, Nov. 10, 5:07 PM
  • Anavex Life Sciences: Interview With Dr. Stephen Macfarlane
    Kanak Kanti De AVXL Tue, Nov. 10, 3:11 PM
  • Arena Beats The Street On Revenue - Company Still Needs Structure To Appreciate
    Spencer Osborne ARNA Tue, Nov. 10, 1:54 PM
  • Gilead: KickStart My Heart
    Dylan Waller GILD Tue, Nov. 10, 11:53 AM
  • MannKind: Weekly Data Updates- 10/30/15 Data
    Looking For Diogenes MNKD Tue, Nov. 10, 9:59 AM
  • Premarket Biotech Digest: Relypsa's Upside Potential, Citron's Next Target, Valeant CEO Sells
    Kanak Kanti De AAVL, AEGR, AGIO Tue, Nov. 10, 8:54 AM
  • Galmed - Interview And Q&A With Josh Blacher, CFO
    Kanak Kanti De's Real-Time Biotech Trade Alerts GLMD Mon, Nov. 9, 12:00 PM
  • Has Celgene's Stock Been Beaten Up Enough?
    DoctoRx AMGN, CE, GILD Mon, Nov. 9, 11:53 AM
  • Is XenoPort Up For Sale?
    ONeil Trader SUPN, XNPT Mon, Nov. 9, 11:13 AM
  • WAVE Life Sciences IPO: Hold Off
    Don Dion ASPX, BMRN, ISIS Mon, Nov. 9, 9:28 AM
  • Updating My Price Target On Gilead Sciences
    Alexander J. Poulos ABBV, BRK.B, ESRX Mon, Nov. 9, 8:44 AM
  • Premarket Biotech Digest: Anavex's Results, Gilead's HCV Sales, Sanofi's Strategic Roadmap
    Kanak Kanti De AGEN, AKRX, AMBS Mon, Nov. 9, 8:23 AM
  • Mesoblast, An Aussie Biotech Cooking Up A Turkey For American Investors
    Alpha Exposure OSIR, TEVA, MBLTY Mon, Nov. 9, 8:18 AM
  • Vivus: Qsymia Sales Still Flat - This Equity Is Treading Water
    Spencer Osborne ARNA, OREX, VVUS Mon, Nov. 9, 7:59 AM
  • Following Up On Charles River Laboratories After The Short-Lived Buying Opportunity
    The Investment Doctor CRL Mon, Nov. 9, 7:24 AM
  • Horizon Pharma: Business As Usual
    ONeil Trader HZNP Mon, Nov. 9, 7:09 AM
  • Arena- Belviq Scripts Present Lowest Market Share To Date
    Spencer Osborne OREX, VVUS, ARNA Mon, Nov. 9, 6:57 AM
  • Lexicon Pharmaceuticals Produces Another Positive Surprise
    Stephen Simpson, CFA SNY, JNJ, LLY Sat, Nov. 7, 10:45 AM
  • Horizon Pharma Shows It's Not Valeant
    Bret Jensen VRX, HZNP Fri, Nov. 6, 4:09 PM
  • Egalet: Plenty Of Cash, Low Market Cap And Strong Growth Prospects
    ONeil Trader EGLT Fri, Nov. 6, 2:34 PM